Sustained-releasing hollow microparticles with dual-anticancer drugs elicit greater shrinkage of tumor spheroids
Metrics: PDF 837 views | HTML 2021 views | ?
Jong-Suep Baek1, Chee Chong Choo2, Nguan Soon Tan2,3,4,5 and Say Chye Joachim Loo1,6
1School of Materials Science and Engineering, Nanyang Technological University, 639798, Singapore
2School of Biological Sciences, Nanyang Technological University, 637551, Singapore
3Lee Kong Chian School of Medicine, Nanyang Technological University, 639798, Singapore
4Institute of Molecular Cell Biology, Proteos, Agency for Science Technology and Research, 138673, Singapore
5KK Research Centre, KK Women’s and Children Hospital, 229899, Singapore
6Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technological University, 637551, Singapore
Say Chye Joachim Loo, email: firstname.lastname@example.org
Keywords: microparticles, controlled-release, PLGA, combination therapy, paclitaxel
Received: July 19, 2017 Accepted: August 04, 2017 Published: August 24, 2017
Polymeric particulate delivery systems are vastly explored for the delivery of chemotherapeutic agents. However, the preparation of polymeric particulate systems with the capability of providing sustained release of two or more drugs is still a challenge. Herein, poly (D,L-lactic-co-glycolic acid, 50:50) hollow microparticles co-loaded with doxorubicin and paclitaxel were developed through double-emulsion solvent evaporation technique. Hollow microparticles were formed through the addition of an osmolyte into the fabrication process. The benefits of hollow over solid microparticles were found to be higher encapsulation efficiency and a more rapid drug release rate. Further modification of the hollow microparticles was accomplished through the introduction of methyl-β-cyclodextrin. With this, a higher encapsulation efficiency of both drugs and an enhanced cumulative release were achieved. Spheroid study further demonstrated that the controlled release of the drugs from the methyl-β-cyclodextrin -loaded hollow microparticles exhibited enhanced tumor regressions of MCF-7 tumor spheroids. Such hollow dual-drug-loaded hollow microparticles with sustained releasing capabilities may have a potential for future applications in cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.